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ABSTRACT
The eukaryotic translation elongation factor 2 (eEF2),
a member of the G-protein superfamily, catalyzes
the post-peptidyl transferase translocation of
deacylated tRNA and peptidyl tRNA to the ribosomal
E- and P-sites. eEF2 is modified by a unique post-
translational modification: the conversion of His699
to diphthamide at the tip of domain IV, the region pro-
posed to mimic the anticodon of tRNA. Structural
models indicate a hinge is important for conforma-
tional changes in eEF2. Mutations of V488 in the
hingeregion andH699inthetipofdomainIVproduce
non-functional mutants that when co-expressed with
the wild-type eEF2 result in a dominant-negative
growth phenotype in the yeast Saccharomyces
cerevisiae.Thisphenotypeislinkedtoreducedlevels
of the wild-type protein, as total eEF2 levels are
unchanged.Changesinthepromoter,50-untranslated
region (50-UTR) or 30-UTR of the EFT2 gene encoding
eEF2 do not allow overexpression of the protein,
showing that eEF2 levels are tightly regulated. The
H699K mutant, however, also alters translation
phenotypes. The observed regulation suggests that
the cell needs an optimum amount of active eEF2
to grow properly. This provides information about
a new mechanism by which translation is efficiently
maintained.
INTRODUCTION
Translation is divided into three steps: initiation, elongation
and termination. Initiation is completed when the initiator
Met-tRNAi
Met and the 80S ribosome are positioned at the
start codon of an open reading frame (ORF) [reviewed in (1)].
During the elongation step, all the subsequent amino acids are
added until a stop codon is reached [reviewed in (2)].
Termination then occurs and the newly formed protein is
released [reviewed (3)]. Translation is highly regulated at
the level of cis-acting mRNA elements, translation factors
and the ribosome [reviewed in (4)]. Regulation via the
mRNA is controlled by elements in the 50- and 30-untranslated
regions (50- and 30-UTR’s), such as upstream ORFs or the
poly(A) tail, respectively [reviewed in (5)]. Translation factors
are modiﬁed by post-translational events such as phosphoryla-
tion, and some ribosomal proteins are regulated by feedback
inhibition, phosphorylation orubiquitination[reviewed in(6)].
The eukaryotic translation Elongation Factor 2 (eEF2) is
a 93 kDa member of the G-protein superfamily. Following
peptide bond formation, eEF2 catalyzes translocation of the
deacylated tRNA in the P-site and peptidyl tRNA in the A-site
into the E- and P- sites, respectively. Thus, the mRNA
advances by three bases to ensure another cycle of elongation.
In Saccharomyces cerevisiae, eEF2 is encoded by two genes,
EFT1 and EFT2. The encoded proteins are identical and one
must be present for viability (7). Yeast eEF2 contains six
structural domains arranged in two blocks, the N-terminal
and C-terminal regions. The N-terminal region consists of
domains I (or G), G0 and II while the C-terminal region has
domains III, IV and V. Elucidation of the crystal structure of
eEF2 showed a reorientation between the N-terminus and the
C-terminus. This reorientation is promoted by a hinge region,
residues 481–489, which undergoes a drastic conformational
change when the apo eEF2 structure is compared with the
sordarin bound eEF2 structure (8).
eEF2 is subjected to two post-translational modiﬁcations.
S.cerevisiae eEF2 is phosphorylated on Thr57 by an endogen-
ous kinase encoded by the RCK2 gene (9). Rck2p is a Ser/Thr
protein kinase homologous to the mammalian calmodulin
kinases, which require phosphorylation for activation
(10,11). eEF2 is phosphorylated in response to osmotic stress,
resulting in lower protein synthesis rates (9). Phosphorylation
reduces the activity of the protein by reducing the afﬁnity for
GTP, but not GDP, and decreasing ribosome binding (12).
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doi:10.1093/nar/gki882Additionally, a histidine in domain IV of eEF2 (H699 in
yeast, and H715 in mammals) is converted to diphthamide.
Diphthamide is the target for ADP ribosylation by Diphtheria
toxin and Pseudomonas aeruginosa exotoxin A, both of which
inactivate the protein (13). ADP ribosylation of eEF2 does not
affect ribosome or nucleotide binding, suggesting inhibition
after eEF2 has bound the ribosome (14). Yeast strains bearing
mutations in H699 of eEF2 can affect cell growth and ADP
ribosylation (15,16).
In the present work, we identiﬁed two dominant-negative
mutants of S.cerevisiae eEF2. Mutagenesis of residues located
in the hinge and tip of domain IV of eEF2, V488A and H699K,
respectively, produced non-functional proteins. This lack of
viability was not the result of the inability to express the
mutants. The total eEF2 protein levels, however, were not
detectably increased with the extra copy of the eEF2 mutant.
Additionally, wild-type eEF2 overexpression plasmids did not
increase total eEF2 levels, inferring that these levels are care-
fully maintained. The dominant-negative phenotype of the
non-functional mutants is predominantly owing to reduced
levels of wild-type functional eEF2. This regulation of
eEF2 levels is not at the level of transcription as seen by
promoter substitutions, via the EFT2 50-o r3 0-UTR, or the
proteasome. The eEF2H699K mutant, however, also causes
dominant effects on total protein synthesis, paromomycin
sensitivity and translation elongation. The eEF2V488A mutant
doesnotconferanydominanttranslationeffects,indicatingthe
translation phenotypes are speciﬁc to an alteration in the anti-
codon mimic loop and not general consequences of reduced
wild-type eEF2 levels. These results suggest that an optimum
amount of eEF2 is necessary for cells to grow and synthesize
proteins efﬁciently. The effect of the mutants supports struc-
tural models of eEF2 function and indicates a potential func-
tion for H699, and the anticodon mimicry loop, in translation.
The regulation of eEF2 levels may further represent a novel
mechanism by which translation is controlled.
MATERIALS AND METHODS
Strains and media
S.cerevisiae strains used in this study are listed in Table 1.
Escherichia coli DH5a cells were used for plasmid prepara-
tion. Standard yeast genetic methods were employed (17).
Yeast cells were grown in either YEPD (1% Bacto yeast
extract, 2% peptone and 2% dextrose) or deﬁned synthetic
complete media (C or C
 ) supplemented with 2% dextrose,
2% rafﬁnose or 2% galactose as the carbon source (18). Yeast
strains were transformed by the lithium acetate method (19).
DNA manipulations and mutagenesis
Recombinant DNA techniques were performed as described
(20). Restriction endonucleases and DNA modifying
enzymes were obtained from Roche or Gibco BRL. Mutations
in EFT2 were created utilizing the PCR based QuikChange
Site-Directed Mutagenesis Kit (Stratagene). pTKB501
(eEF2
HA, provided by Dr M. Justice, Merck Research Labor-
atories) and pTKB612 [eEF2
HIS, (21)] were utilized as the
templates for PCR. pTKB658 (eEF2
HIS
V488A) and pTKB696
(eEF2
HA
V488A) were created using primers 50V488A
(50-CTCTGTCTCTCCAGCTGTGCAAGTCGCTGTCG-30)
and 30V488A (50- CGACACCGACTTGCACAGCAGGAGA-
GACAGAG-30). pTKB701 (eEF2
HA
H699K) and pTKB704
(eEF2
HIS
H699K) were created using primers 50H699K (50-
CATGCCGATGCTATCAAGAGAGGTGGTGGTCAAAT-
C-30) and 30H699K (50-GATTTGACCACCACCTCCCTT-
GATAGCATCGGCATG-30). All mutations were conﬁrmed
by restriction digestion and DNA sequence analysis.
Cell growth
Growth of strains containing either eEF2 under the GAL1
promoter or the empty vector control was performed by grow-
ing cells to an A600 of 1.0 inC-Leu liquid media.Serial 10-fold
dilutions (10 ml each) were spotted on C-Leu and C-Leu plus
galactose media followed by incubation at 13, 24, 30 and 37 C
for 3–7 days. For galactose induction experiments cells were
grown to an A600 of 0.5 in C-Leu plus rafﬁnose, washed with
water, and transfered to C-Leu plus galactose. Samples were
taken for protein extraction, RNA extraction and ﬂow cyto-
metry prior to washing as well as following induction with
galactose for 0.5, 1, 2, 3, 5, 7.5, 9, 12 and 24 h. Doubling times
were determined by growing strains in C-Leu at 30 C starting
with an A600 of 0.1 and monitoring the A600 for 12 h.
Sensitivity to translation inhibitors and protein
synthesis rates
Halo assays for sensitivity to cycloheximide, paromomycin
and hygromycin B were performed as described previously
(22). Microtiter assays in liquid culture were performed for at
least three independent colonies of each strain grown at 30 C
in C-Leu to mid-log phase, diluted to A600 of 0.1 and grown
at 30 C in triplicate in 96-well microtiter plates with varying
concentrations of paromomycin. Growth was monitored on a
Bio-Tek Elx 800 microtiter reader, and reported as the mean
of the triplicate A600 at 24 h. For in vivo [
35S]methionine
incorporation assays yeast strains were grown in liquid cul-
tures (100 ml) in C-Met-Leu at 30 C to mid-log phase and
assayed as described (22). All time points were analyzed in
triplicate.
Western blot analysis
Cells were harvested by centrifugation, suspended in lysis
buffer [50 mM Tris–HCl, pH 7.5, 50 mM NaCl, 1 mM
DTT, 0.2 mM phenylmethylsulphonyl ﬂuoride and 10%
Table 1. S.cerevisiae strains
Strain Genotype Reference
YEFD12 h MATa ade2 leu2 ura3 his3 trp1 eft1::HIS3
eft2::TRP1 pEFT1 URA3 CEN (15)
TKY675 MATa ade2 leu2 ura3 his3 trp1 eft1::HIS3
eft2::TRP1 pEFT2-6·His LEU2 CEN (21)
TKY751 MATa ade2 leu2 ura3 his3 trp1 eft1::HIS3
eft2::TRP1 pEFT2-HA LEU2 CEN This work
TKY918 MATa ade2 leu2 ura3 his3 trp1 eft1::HIS3
eft2::TRP1 pEFT2-6·His URA3 2m This work
YPG499 MATa ura3-52 leu2-D0 his3-D200 trp1-D63
lys2-801 ade2-101 (29)
CMM806 MATa ura3-52 leu2-D0 his3-D200 trp1-D63
lys2-801 ade2-101 cim5-1 (29)
KMY851 MATa ura3-D5 his2-1 leu2-2 pre1-1 pre2-2 K. Madura
Nucleic Acids Research, 2005, Vol. 33, No. 18 5741glycerol] and lysed with glass beads (18). Total protein was
determined by Bradford protein analysis (BioRad, Hercules,
CA) and 1 mg was separated by SDS–PAGE and transferred to
nitrocellulosemembranes.Membraneswere probedwith poly-
clonal antibodies to yeast eEF2 (1:20000 dilution), Pgk1p
(1:10000 dilution) or a monoclonal antibody to the hema-
glutinin (HA) tag (1:250 dilution) and detected by a second-
ary antibody conjugated to peroxidase (1:7500 dilution;
Amersham ECL plus).
Polyribosome analysis
Yeast polyribosome analysis was performed as described pre-
viously (23) with the following speciﬁcations. Yeast cultures
were grown in C-Leu at 30 C to mid-log phase, divided, and
extracted with and without cycloheximide added to the cells
and lysis buffer [10 mM Tris–HCl, pH 7.5, 100 mM NaCl,
30 mM MgCl2, 200 mg/ml heparin and 0.2% diethyl pyrocar-
bonate]. Cell extracts (30 A260) were layered on 35 ml 7–47%
sucrose gradients and centrifuged for 4 h at 27000 r.p.m. in
a Beckman SW28 rotor. The A254 was monitored using
a Model 185 density gradient fractionator (ISCO, Inc.,
Lincoln, NE).
Northern blot analysis
Cells were harvested by centrifugation and total RNA was
isolated as described (24). RNA was separated on a 1% form-
aldehyde agarose gel, transferred to Hybond plus membranes
overnight by capillary action and crosslinked to the membrane
with a Spectrolinker XL-1000 (Spectronics). Hybridization
and detection were performed as per the ExpressHyb protocol
(Clonetech).
32P-labeled probes for yeast EFT2 and ACT1
were prepared with the Rad Prime Labeling System kit
(Invitrogen). Northern blots were detected using a Phosphor-
imager Typhoon 9410 (Molecular Dynamics) and quantiﬁed
with the ImageQuant program (Molecular Dynamics).
RESULTS
eEF2V488A and eEF2H699K mutations confer
dominant-negative phenotypes
Based on the X-ray crystal structure of eEF2, the functions of
the domain III hinge region and the tip of domain IV were
addressed with mutations targeting residues V488 and H699
(Figure 1). The hinge region (amino acids 481–489) is 93%
identical in eukaryotes and undergoes a conformational
change between the crystal structures of apoeEF2 in compar-
ison with eEF2 bound to the anti-fungal drug sordarin (8). The
hinge region is hypothesized to be essential for the conforma-
tional change of eEF2. H699 is located at the tip of domain IV
and is post-translationally modiﬁed to diphthamide. Diphth-
amide is the site of ADP ribosylation by Diphtheria toxin and
Pseudomonas exotoxin A (13). This tip has been shown to be
in close proximity to the decoding site of the ribosome by
cryoelectron microscopy, suggesting it is needed for prevent-
ing frameshifting of the mRNA (25). To differentiate between
the wild-type and mutant eEF2 proteins, the mutants were
expressed with either a HA or 6· His tag. The HA tag does
not interfere with function as eEF2
HA can complement the loss
of wild-type eEF2 (Figure 2A) and had identical sensitivity to
H699
V488
Figure 1. Structure of yeast eEF2 indicates the location of V488 in the poly-
linkerregionandH699atthetipofdomainIV.Thestructurewasproducedwith
the PyMOL program (37), using PDB 1NOV coordinates (8).
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Figure 2. eEF2V499A and eEF2H699K are unable to function as the only form of
eEF2 in vivo and confer a dominant-negative phenotype. (A) YEFD12h trans-
formed with pRS315 (empty), pTKB615 (eEF2), pTKB501 (eEF2
HA),
pTKB696 (eEF2
HA
V488A) and pTKB701 (eEF2
HA
H699K) were streaked on C-Leu
or 5-FOA and incubated from 3 to 7 days at 30 C. (B) Western blot analysis
against the HA tag shows that the mutant proteins are expressed. Lanes are
empty vector, eEF2
HA, eEF2
HA
V488A and eEF2
HA
H699K. Protein extracts were pre-
pared,resolvedbySDS–PAGE,anddetectedwithantibodiesagainstHA,eEF2
and Pgk1p (loading control).
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shown previously to be functional as the only form of eEF2
(21). Alanine was selected for mutagenesis of V488 to min-
imize the side chain while H699K was demonstrated in pre-
vious work to confer a dominant growth phenotype (16).
Plasmids expressing HA tagged eEF2
HA
V488A or eEF2
HA
H699K
were transformed into yeast strain YEFD12h. The mutations
result in non-functional eEF2 proteins, as shown by their inab-
ility to grow on media containing 5-FOA (Figure 2A). The
lack of function is not owing to the lack of expression of the
mutants as monitored by western blot analysis with an HA
antibody (Figure 2B). The 6· His tagged wild-type or mutant
eEF2 proteins could not be recognized by an anti 6· His
monoclonal antibody, but expression was conﬁrmed by Ni-
NTA pulldown and Coomassie staining of the SDS–PAGE gel
(data not shown). Surprisingly, the total eEF2 protein levels
were essentially identical when the empty vector or an addi-
tional eEF2 expressing plasmid were present, indicating the
inability to overexpress the protein (Figure 2B). To monitor
theamountofco-expressedHAtaggedmutanteEF2,eEF2and
HA antibody recognition was standardized via western blot
analysis. Subsequent quantitative analysis of the recognition
of total eEF2 (eEF2 antibody) and HA-tagged eEF2 (HA anti-
body) demonstrated that eEF2
HA constituted  60% of total
eEF2 while eEF2
HA
V488A constituted 44%. The co-expression
of the mutant forms with wild-type eEF2 resulted in a slow-
growth phenotype on C-Leu (Figure 2A), indicating a
dominant-negative phenotype. In a systematic mutagenesis
study of H699 the dominant phenotype of eEF2H699K was
noted, however, the mechanism of the effect is undetermined
(16). The growth effect was not the result of the HA tag on the
mutant, as growth defects were also observed with an addi-
tional copy of either untagged and 6· His tagged eEF2V488A or
eEF2H699K (data not shown). The phenotype observed on solid
mediaisalsoevidentinliquidmedia,wherethedoublingtimes
of strains expressing a mutant form of eEF2 increased up to
2-fold (Table 2).
The dominant-negative phenotype of eEF2 mutants is
due to similar effects on eEF2 levels except differential
effects on translation functions
The dominant-negative phenotype observed for the two eEF2
mutants could be due to either reduced levels of functional
(wild-type) protein or obstruction of eEF2’s function in trans-
lation. To address these possibilities we examined the effect of
eEF2V488A and eEF2H699K expression on translation activity.
Strains expressing wild-type eEF2, an empty vector, or an
extra plasmid with wild-type or a mutant form of eEF2
were examined for their effect on total protein synthesis by
[
35S]methionine incorporation. No signiﬁcant effect on total
translation was observed with co-expression of wild-type
eEF2 or eEF2V488A (Figure 3A). Co-expression of
eEF2H699K, however, showed a consistent 20% decrease in
total protein synthesis >60 min of growth (Figure 3A). Effects
on protein synthesis were also monitored by sensitivity to the
translation inhibitors cycloheximide, paromomycin and
hygromycin B. Co-expression of wild-type or mutant forms
of eEF2 caused no changes in cycloheximide or hygromycin B
resistance, while paromomycin sensitivity was uniquely
increased for cells co-expressing eEF2H699K (Table 3). The
altered drug sensitivity was quantiﬁed in a liquid microtiter
growth assay in the presence of increasing concentrations of
these compounds. Similar to the halo assay, sensitivity to
cycloheximide and hygromycin B were not altered (data not
shown). Paromomycin sensitivity was increased  5-fold only
with co-expression of eEF2H699K (Figure 3B).
Polyribosome proﬁle analysis was used to determine
whether the elongation step of protein synthesis was affected.
Standard polyribosome proﬁles of extracts prepared in the
presence of cycloheximide showed no signiﬁcant difference
in the levels of free 40S or 60S ribosome subunits, 80S
monoribosomes or translating ribosomes in the polyribosome
region between strains co-expressing wild-type or either eEF2
mutant (Figure 3C, top panel). When cycloheximide is
excluded from the preparation of the extracts, ribosomes con-
tinue elongating on the mRNA, complete translation, and
move to lower order polyribosomes or the 80S peak (26). A
strain expressing eEF2H699K shows a higher amount of polyri-
bosomes in the absence of cycloheximide than strains
co-expressing wild-type or eEF2V488A (Figure 3C, lower
panel). Thus, eEF2H699K uniquely shows a reduction in
most probably elongation, although other post-initiation
events such as termination or ribosome recycling cannot be
ruled out with this assay. The total protein synthesis, drug
sensitivity and polyribosome analysis results suggest that
the effects conferred by eEF2H699K are consistent with an
inhibition of translation elongation. Thus, the different results
obtained with the mutants show that the more severe dominant
phenotype of eEF2H699K is probably caused by dominant
effects on translation and reduced active eEF2, while
eEF2V488A shows a less severe dominant growth effect
owing to only reduced active eEF2 levels.
The promoter, 50-UTR or 30-UTR do not confer the
inability to increase eEF2 levels
In order to determine the role of the promoter and UTR ele-
ments on the ability to increase eEF2 levels, a series of altered
EFT2 expression constructs were prepared. Both CEN (low
copy) and 2m (high copy) plasmids expressing eEF2 from
EFT2 were used (Figure 4A). The constructs expressed
eEF2 under the EFT2 or TEF5 constitutive promoters, and
were epitope-tagged to assure that the plasmid-borne alleles
were expressed. The 30-UTR’s from EFT2 were substituted by
HA or 6· His tags. The untagged EFT2 plasmid with the
authentic 50- and 30-UTR’s, and the EFT2 constructs with
the HA or 6· His tag replacing the 30-UTR all produced
equal amounts of protein when present as the only form of
eEF2 (data not shown). Plasmids were transformed into yeast
Table 2. Doubling times of YEFD12h with a plasmid expressing the indicated
form of eEF2
YEFD12h + Doubling time (min)
Empty vector 99 ± 6
eEF2 95 ± 5
eEF2
HA 124 ± 7
eEF2
HA
V488A 137 ± 4
eEF2
HA
H699K 210 ± 2
Doubling times were determined by growing strains in C-Leu at 30 C starting
withanA600of0.1andmonitoringtheA600over12h.AlltheeEF2plasmidshave
the authentic EFT2 promoter. The results are the average of three experiments.
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a CEN EFT2 plasmid to allow survival. Cells were maintained
in selective media, and the total amount of eEF2 protein was
analyzed by western blot analysis (Figure 4B). eEF2 protein
levels were unchanged in the presence of a plasmid with the
EFT2 gene including the authentic promoter and the 50- and 30-
UTR’s, or with a low or high copy number plasmid with eEF2
expressed from the TEF5 promoter (Figure 4B). Additionally,
the eEF2
HA CEN constructs lacking the EFT2 30-UTRbut with
the EFT2 promoter and 50-UTR resulted in unchanged levels
of eEF2. The inability to overexpress the eEF2 protein is not
owing to a defect in the expression of the plasmid-borne eEF2
gene, as western analysis with the HA antibody conﬁrms that
the eEF2
HA is expressed (data not shown). eEF2
HIS expression
was conﬁrmed by Ni-NTA pulldown and Coomassie staining
of the SDS–PAGE gel (data not shown). These results show
that eEF2 levels remain unchanged despite altering the pro-
moter or 50-o r3 0-UTR’s.
Overexpression was also attempted by expressing eEF2
HIS
under the GAL1 galactoseinduciblepromoter inthe absenceof
the EFT2 50- and 30-UTR’s (Figure 5A). This plasmid com-
plemented for the loss of wild-type eEF2 plasmid in media
containing galactose (data not shown). Growth of the trans-
formed strain on C-Leu media with glucose as the carbon
source was essentially wild-type. A slight slow growth pheno-
type was observed when the same cells were shifted to C-Leu
plus galactose (Figure 5B). This result suggests that excess
eEF2 was transiently expressed and has a negative impact on
cell growth seen only early in the induction stage and not when
steady state is reached. To conﬁrm that eEF2 was transiently
overexpressed from this plasmid, western blot analysis was
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Figure 3. Strains expressing eEF2H699K affect translation at the elongation step. (A) Strain YEFD12h expressing no additional copies of eEF2 (pRS315, crosses),
eEF2(pTKB612,diamonds),eEF2V488A(pTKB658,squares)oreEF2H699K(pTKB704,triangles)weregrowninC-Met-Leutomid-logphase.[
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Table 3. Drug sensitivities of YEFD12h with a plasmid expressing the
indicated form of eEF2
YEFD12h + 1m M
Cycloheximide
800 mg/ml
Paromomycin
100 mM
Hygromycin B
Empty vector 39 ± 1 mm
a 12 ± 2 9 ± 0
eEF2 40 ± 1 12 ± 1 10 ± 1
eEF2
HA 41 ± 1 12 ± 1 10 ± 1
eEF2
HA
V488A 41 ± 2 12 ± 1 10 ± 1
eEF2
HA
H699K 43 ± 1 21 ± 1 10 ± 1
aSensitivity was determined by measuring the diameter of inhibition of growth
(in mm) around a filter disk containing 10 ml of the indicated drug. Cells were
plated on C-Leu and grown at 30 C. All the eEF2 plasmids have the authentic
EFT2 promoter. The results shown are the average of three experiments.
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Figure 5. TransientoverexpressionofeEF2demonstratesproteinlevelsarereducedbeforemRNAlevels.(A)ConstructinwhicheEF2isexpressedundertheGAL1
galactoseinduciblepromoter.(B)YEFD12hwastransformedwithpRS315(empty)andpTKB763(GAL1eEF2
HIS).Cellsweregrowntomid-logphaseat30 CinC-
Leu liquid media then spotted as 10-fold serial dilutions on C-Leu and C-Leu plus galactose. (C) Protein extracts were prepared from the strains as in (B), grown to
steady state in the absence and presence of galactose. Total proteins were resolved by SDS–PAGE and detected with antibodies against eEF2 and Pgk1p. The fold
expression is calculated relative to Pgk1p levels. (D) YEFD12h with pTKB763 (GAL1 eEF2
HIS) was grown to mid-log phase in C-Leu plus raffinose media and a
sampletaken.Theculturewasharvested,washedwithwaterandresuspendedinC-Leuplusgalactose.Subsequentlysamplesweretakenforeachtimepoint,protein
extractsprepared,resolvedbySDS–PAGEanddetectedwithantibodiesagainsteEF2andPgk1p.ThenumbersindicateeEF2expressionrelativetoPgk1plevels.The
bar graph shows eEF2 expression levels at each galactose time point relative to expression in raffinose media. (E) RNA extracts were prepared from the same time
pointsas (D), resolved by a formaldehyde agarosegel and detectedwith probes againstEFT2 and ACT1 (loading control). The numbersindicate mRNA expression
from each eEF2-expressing plasmid relative to ACT1. The bar graph shows total EFT2 mRNA expression relative to ACT1 mRNA.
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2 days to reach steady state. In this case no growth defect was
observed and eEF2 levels were unchanged compared with
the empty vector control (Figure 5C). Expression was sub-
sequently induced from the GAL1 promoter and eEF2 protein
levels were determined over time. Cells where the extra copy
of eEF2 is expressed from the GAL1promoter were grown on
C-Leu plus rafﬁnose to repress expression, transferred to
C-Leu plus galactose to induce expression, and eEF2 protein
levels were monitored from 0 to 24 h by western blot analysis
(Figure 5D). The eEF2 protein levels transiently increased
4-fold at 9.5 h, but subsequently reduce by half at the longest
time point.
To examine whether the effect observed at the protein level
was also observed at the mRNA level, total mRNA was pre-
pared from matched samples and the eEF2 mRNA levels mon-
itored (Figure 5E). eEF2 mRNA produced from the authentic
eEF2 promoter versus the GAL1 promoter was differentiated
by differences in 30-UTR lengths. The GAL1 expression plas-
mid utilizes a cryptic transcription terminator and thus creates
a speciﬁc but larger mRNA. The results from the western blot
analysis (Figure 5D) show this mRNA is translated, although
the longer mRNA could potentially alter other events such as
stability. The GAL1 induced eEF2 mRNA levels rose, peaked
at 9.5 h and remained elevated for a longer period than the
protein levels. The initial appearance of the GAL1-dependent
eEF2 mRNA correlated with a slight reduction in the EFT2
and ACT1 mRNA levels owing to the carbon source change,
which quickly returned to wild-type. Since excess eEF1A
alters the cell cycle progression of yeast (27) we determined
the effect oftransient overexpression ofeEF2 on the cellcycle.
Flow cytometry analysis of matched samples from all time
points of the galactose induction experiment showed no
change in G1 and G2/M distribution when compared with
cells transformed with an empty vector (data not shown).
Based on the lack of overexpression with promoter, 50 and
30-UTR alterations, we hypothesized that the regulation of
eEF2 levels is probably post-transcriptional. A major mech-
anism that regulates protein levels involves degradation by the
26Sproteasome[reviewedin(28)].To address theeffectofthe
proteasome on the regulation of eEF2 levels, the proteasome-
deﬁcient cim5–1 and pre1-1, pre2-2 mutants were used. The
cim5-1mutationlies in the 19S proteasome regulatory subunit,
while the pre1-1, pre2-2 mutant affects the 20S catalytic sub-
unit. These mutations have been shown to decrease
proteasome-dependent protein degradation (29). The different
subunit locations of these mutants allow for a study that is
independent of the proteasome regulatory or catalytic func-
tion. pTKB695 (EFT2
HIS, 2m, TEF5 promoter) or the empty
vector was transformed into the proteasome mutant and con-
trol strains. eEF2 protein levels and growth were unchanged
(data not shown), indicating the inability to overexpress eEF2
is proteasome-independent.
DISCUSSION
eEF2 plays a key role in the essential process of protein
synthesis by translocating tRNA’s from the ribosomal A-
and P-sites to the P- and E-sites, respectively, and allowing
a new round of peptide bond formation to occur. As with other
factors involved in translation, eEF2 is regulated by mechan-
isms that alter the outcome of protein synthesis. eEF2 is post-
translationally modiﬁed by phosphorylation of Thr57. The
effect of the diphthamide modiﬁcation on H699, the target
site for ADP ribosylation, is not well understood. eEF2
is also a target for natural products, binding the compound
sordarin in a hinge region altered between conformations.
V488 is located in the hinge region of eEF2. This region
consists of amino acids 481–489 and undergoes substantial
changes in conformation in the presence and absence of the
inhibitor sordarin (8). These structures show that eEF2 prob-
ably changes conformation during its function by a reorienta-
tion of the C-terminal domains III, IV and V relative to
domains I, G0 and II. Cryoelectron microscopy structures of
the yeast ribosome with eEF2 in the presence of sordarin show
changes relative to the apo eEF2, supporting the need for eEF2
to change conformation to perform its function (25). Similar
changes in conformation have been observed for other G-
proteins (30). eEF2V488A is a stable but non-functional
eEF2 protein, highlighting the dependence of this region for
eEF2 function in vivo.
Mutations in H699 inhibit the modiﬁcation of this residue to
diphthamide (16). eEF2H699K is a stable, but non-functional
protein in vivo. This residue is located at the tip of domain IV,
which is proposed to mimic the anticodon arm of tRNA. The
cryoelecton microscopy structure of the yeast ribosome in the
presence of eEF2 and sordarin demonstrates that the tip of
domain IV is in close proximity to the ribosome decoding site
mRNA (25). Based on this location, it is hypothesized that this
tip is involved in stabilizing codon–anticodon pairing during
translocation, thus preventing ﬁdelity errors. The structure of
ADP ribosylated eEF2 and its binding afﬁnity to the ribosome
further suggest the importance of this region in the function of
eEF2 (14). Here we have shown that expressing eEF2H699K in
the presence of the wild-type eEF2 conferred not only the slow
growth phenotype observed for the non-functional eEF2V488A,
but also resulted in dominant effects that decrease total protein
synthesis and slow elongation. The sensitivity to paromomy-
cin observed may be a further indication of altered translation
at the level of ﬁdelity (31,32). Thus, our in vivo results support
the hypothesized function of the tip of domain IV in efﬁcient
and accurate translation.
InbothcasesthemutantproteinisaportionofthetotaleEF2
pool, which remains ﬁxed. This results in a reduction in the
level of wild-type eEF2 protein. Thus, the reduced pool of
wild-type eEF2 contributes to the dominant-negative slow
growth phenotype. Given that the expression levels of the
eEF2V488A and eEF2H699K mutants are essentially the same
(Figure 2B), the difference in the inhibition of growth is prob-
ably caused by dominant effects on protein synthesis. Thus,
eEF2V488A predominantly causes reduced functional eEF2
proteinlevelswhileeEF2H699Kcausesamoresigniﬁcanteffect
owing to both a decrease in wild-type eEF2 protein levels and
a dominant-negative effect on protein synthesis.
Despite the different effects seen by the co-expression of
eEF2V488A and eEF2H699K, one thing they have in common is
the reduced level of wild-type eEF2 protein. eEF2 protein
levels are also unchanged between a wild-type strain and
those also expressing one of a series of wild-type eEF2 con-
structs. This result is not owing to the inability to express the
plasmid-borne genes, as shown by methods that recognize the
5746 Nucleic Acids Research, 2005, Vol. 33, No. 18tagged forms of eEF2. Using either low or high copy plasmids
or changing the promoter, 50-o r3 0-UTR did not allow eEF2
overexpression. Thus, a post-transcriptional control mechan-
ism regulates eEF2 levels. Our studies have shown previously
that overexpression of the other translation elongation factors
have different effects. eEF1A overexpression results in a slow
growth phenotype, however, this phenotype is due to effects
on the actin cytoskeleton and is not linked to protein synthesis
(27). Overexpression of eEF1Ba also resulted in a slow
growth phenotype without affecting actin or protein synthesis.
Overexpression of eEF1Bg has no effect on cell growth (22),
while excess eEF3 enhances growth (22,33). Thus, overex-
pression can be achieved for all the elongation factors except
eEF2. A recent report has shown that in mouse adipocytes in
which the insulin receptor has been knocked out, eEF2 protein
but not mRNA levels decrease (34). This supports a mechan-
ism that regulates the eEF2 protein levels independent of
transcription. Thus, eEF2 levels are probably regulated by
a feedback mechanism similar to that observed with other
components of the translational machinery such as ribosomal
proteins (RPs) [reviewed in (35)]. Some RPs bind their own
mRNA to regulate their expression via a post-transcriptional
mechanism in splicing or translation, such as yeast rpL30 (36).
The inability to overexpress eEF2 and the dominant-
negative phenotypes obtained with the non-functional mutants
infers the need for an optimum amount of wild-type eEF2 in
the cell for proper function. However, the differing ability of
the two mutants to alter protein synthesis shows that H699
playsanimportant role inprotein synthesis.Furtheranalysisof
domain IV mutants in the anticodon mimic region will deﬁne
the precise role of this critical region in eEF2 function. It is
clear from the regulation of eEF2 by phosphorylation (9) and
protein levels regulation (this work) that eEF2 function is an
important regulatorystepingeneexpression.Theregulationof
eEF2 protein levels provides a new mechanism by which
protein synthesis is controlled during elongation.
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